Pilot feasibility randomised sham-controlled trial of electroacupuncture for taxane-induced peripheral neuropathy in Breast Cancer patients during treatment

Start Date02 Jun 2022

Sponsor / Collaborator-

JPRN-jRCTs032210221 / CompletedPhase 2IIT

Effects and safety of prophylactic compression therapy for taxane-induced peripheral neuropathy

Start Date07 Oct 2021

Sponsor / Collaborator-

100 Clinical Results associated with Proliposomal intravesical paclitaxel

100 Translational Medicine associated with Proliposomal intravesical paclitaxel

100 Patents (Medical) associated with Proliposomal intravesical paclitaxel

Literatures (Medical) associated with Proliposomal intravesical paclitaxel

01 Oct 2024·International Journal of Pharmaceutics

Development of a proliposomal pretomanid dry powder inhaler as a novel alternative approach for combating pulmonary tuberculosis

Article

Author: Ali Khumaini Mudhar Bintang, Muhammad ; Das, Shyamal C. ; Srichana, Teerapol ; Das, Shyamal C ; Aekwattanaphol, Nattanit ; Nakpheng, Titpawan ; Khadka, Prakash

Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) continue as public health concerns. Inhaled drug therapy for TB has substantial benefits in combating the causal agent of TB (Mycobacterium tuberculosis). Pretomanid is a promising candidate in an optional combined regimen for XDR-TB. Pretomanid has demonstrated high potency against M. tuberculosis in both the active and latent phases. Conventional spray drying was used to formulate pretomanid as dry powder inhalers (DPIs) for deep lung delivery using a proliposomal system with a trehalose coarse excipient to enhance the drug solubility. Co-spray drying with L-leucine protected hygroscopic trehalose in formulations and improved powder aerosolization. Higher amounts of L-leucine (40-50 % w/w) resulted in the formation of mesoporous particles with high percentages of drug content and entrapment efficiency. The aerosolized powders demonstrated both geometric and median aerodynamic diameters < 5 µm with > 90 % emitted dose and > 50 % fine particle fraction. Upon reconstitution in simulated physiological fluid, the proliposomes completely converted to liposomes, exhibiting suitable particle sizes (130-300 nm) with stable colloids and improving drug solubility, leading to higher drug dissolution compared to the drug alone. Inhalable pretomanid showed higher antimycobacterial activity than pretomanid alone. The formulations were safe for all broncho-epithelial cell lines and alveolar macrophages, thus indicating their potential suitability for DPIs targeting pulmonary TB.

01 Feb 2022·Nature MedicineQ1 · MEDICINE

AAV gene therapy for Tay-Sachs disease

Q1 · MEDICINE

Article

Author: Tai, Phillip W L ; Gounis, Matthew ; Gray-Edwards, Heather L ; Eichler, Florian S ; Sena-Esteves, Miguel ; Shazeeb, Mohammed Salman ; Bateman, Scot ; Martin, Douglas R ; Mueller, Christian ; Gernoux, Gwladys ; Moser, Richard ; Brown, Robert H ; Gibson, Laura ; Rohatgi, Saurabh ; Barton, Bruce A ; Vardar, Zeynep ; McKenna-Yasek, Diane ; Parzych, Julia ; Puri, Ajit ; Tifft, Cynthia J ; Douthwright, Catherine ; Cataltepe, Oguz ; Abayazeed, Aly ; Blackwood, Meghan ; Jiang, Xuntian ; Spanakis, Spiro G ; Batista, Ana Rita ; Flotte, Terence R ; Finberg, Robert ; Keeler, Allison M

Tay-Sachs disease (TSD) is an inherited neurological disorder caused by deficiency of hexosaminidase A (HexA). Here, we describe an adeno-associated virus (AAV) gene therapy expanded-access trial in two patients with infantile TSD (IND 18225) with safety as the primary endpoint and no secondary endpoints. Patient TSD-001 was treated at 30 months with an equimolar mix of AAVrh8-HEXA and AAVrh8-HEXB administered intrathecally (i.t.), with 75% of the total dose (1 × 10¹⁴ vector genomes (vg)) in the cisterna magna and 25% at the thoracolumbar junction. Patient TSD-002 was treated at 7 months by combined bilateral thalamic (1.5 × 10¹² vg per thalamus) and i.t. infusion (3.9 × 10¹³ vg). Both patients were immunosuppressed. Injection procedures were well tolerated, with no vector-related adverse events (AEs) to date. Cerebrospinal fluid (CSF) HexA activity increased from baseline and remained stable in both patients. TSD-002 showed disease stabilization by 3 months after injection with ongoing myelination, a temporary deviation from the natural history of infantile TSD, but disease progression was evident at 6 months after treatment. TSD-001 remains seizure-free at 5 years of age on the same anticonvulsant therapy as before therapy. TSD-002 developed anticonvulsant-responsive seizures at 2 years of age. This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.

01 May 2016·Anesthesia & AnalgesiaQ2 · MEDICINE

Proliposomal Ropivacaine Oil: Pharmacokinetic and Pharmacodynamic Data After Subcutaneous Administration in Volunteers

Q2 · MEDICINE

Article

Author: Aharon, Arnon ; Davidson, Elyad M. ; Ginosar, Yehuda ; Kagan, Leonid ; Naveh, Michael ; Haroutounian, Simon

BACKGROUND:Slow-release liposomal formulations of local anesthetics prolong plasma redistribution and reduce peak plasma drug concentration, allowing safer administration of larger doses and further prolonging sensory effects. However, their clinical applicability is limited by expensive manufacture and liposomal leakage. Previously, we described the simple preparation of a novel proliposomal ropivacaine oil that produces multilamellar liposomal vesicles on exposure to aqueous media and that has a shelf-life of >2 years at room temperature. In this study, we present both pharmacodynamic and pharmacokinetic data in healthy volunteers after subcutaneous injection of this novel proliposomal preparation of ropivacaine.METHODS:In the pharmacodynamic phase of this study, 15 volunteers received 3 separate subcutaneous injections of 2.5 mL containing 1 of the following drugs: proliposomal 4% ropivacaine, plain 0.5% ropivacaine, and the ropivacaine-free proliposomal vehicle. Drugs were administered into the lower back, and their location was randomized and blinded; a separate area was used as an uninjected, open control. Experimental sensory assessment was made at repeated intervals over 72 hours using both pinprick sensation and experimental heat pain tolerance (assessed using quantitative sensory testing). In a separate pharmacokinetic phase of this study, 9 volunteers received subcutaneous injections of 2.5 mL of either proliposomal 4% ropivacaine (n = 6) or plain 0.5% ropivacaine (n = 3); these participants had plasma ropivacaine concentrations assessed at repeated intervals over 72 hours.RESULTS:The mean ± SE duration of pinprick anesthesia after proliposomal and plain ropivacaine administration lasted 28.8 ± 6.0 and 15.9 ± 3.5 hours, respectively (mean difference, 16.8 hours; 95% confidence interval, 10.0–23.7; P = 0.001). For experimental heat pain, the anesthesia duration was approximately 36 and 12 hours, respectively, with mean ± SE area under the curve of the normalized heat pain tolerance over time 55.0 ± 28.8 Δ°C·min for proliposomal ropivacaine and 9.6 ± 26.0 Δ°C·min for plain ropivacaine (mean difference, 64.6 Δ°C·min; 95% confidence interval, 10.2–119.0; P = 0.036). In the pharmacokinetic study, there was no significant difference in peak plasma concentration in the proliposomal ropivacaine group (164 ± 43 ng/mL compared with 100 ± 41 ng/mL in the plain ropivacaine group; P = 0.07) despite an 8-fold increase in ropivacaine dose in the proliposomal group. The 99% upper prediction limit for peak plasma concentrations (351 ng/mL proliposomal; 279 ng/mL plain) was well below the putative toxic plasma concentration for both groups. The mean ± SE terminal half-life and area under the curve for proliposomal ropivacaine versus plain ropivacaine were 13.8 ± 3.6 hours vs 5.9 ± 2.3 hours (P = 0.011) and 5090 ± 1476 h·ng/mL vs 593 ± 168 h·ng/mL (P = 0.0014), respectively.CONCLUSIONS:The prolonged pharmacodynamic effect of proliposomal ropivacaine, together with its delayed elimination and prolonged redistribution to plasma, is compatible to depot-related slow-release and similar to the performance of other liposomal local anesthetics. The advantage of the proliposomal oil is its ease of preparation and its extended shelf-stability at room temperature.

News (Medical) associated with Proliposomal intravesical paclitaxel

08 Apr 2024

·www.biospace.com

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified cancers Third poster presentation to highlight the potential role of ecDNA-based resistance to chemotherapy SAN DIEGO--(BUSINESS WIRE)-- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024. BBI-355 is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTENTIATE clinical trial in patients with oncogene amplified cancers. “Extrachromosomal DNA afford unique advantages to tumors, typically rendering existing therapies ineffective and correlating with poor patient outcomes,” said Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio. “Our first poster presented this year at AACR demonstrated that BBI-355 overcame ecDNA-mediated targeted therapy resistance in preclinical tumor models by leveraging the enhanced reliance of ecDNA-driven tumor cells on CHK1 for survival. BBI-355 showed substantial antitumor activity, including complete and durable regressions, in preclinical oncogene amplified models. Dr. Hassig continued, “Today we present preclinical and preliminary clinical pharmacodynamic biomarker assay data that showed detection of CHK1 inhibition-associated replication stress in both patient skin and tumor tissue following administration of BBI-355. In addition, we report a possible role for ecDNA in acquired resistance to chemotherapy observed in preclinical models, extending the potential applicability of ecDNA-directed strategies beyond targeted therapy resistance. We are encouraged by these findings as we continue to advance BBI-355 through the ongoing Phase 1/2 POTENTIATE clinical trial.” Details of the presentations are as follows: Title: Oral CHK1 inhibitor BBI-355 allows flexibility of dose and schedule with demonstration of monotherapy and combinational antitumor activity in extrachromosomal DNA (ecDNA)-driven oncogene amplified preclinical models Abstract Number: 613 Session Category: Experimental and Molecular Therapeutics Session Title: Kinase and Phosphatase Inhibitors 1 Session Date and Time: Sunday Apr 7, 2024, 1:30 PM – 5:00 PM PT Location: Poster Section 25 Poster Board Number: 23 BBI-355 showed inhibition of CHK1 in a host of tumor cell lines and demonstrated in vivo single agent tumor growth inhibition, including complete tumor regressions, across a range of tumor models representing multiple different oncogene amplifications and tumor types. BBI-355 also demonstrated synergistic tumor growth inhibition, including durable regressions, when combined with targeted therapies across multiple oncogene amplified tumor models. Title: Preclinical and clinical pharmacodynamic characterization of BBI-355, a novel, orally bioavailable, and selective CHK1 inhibitor being evaluated in the first-in-human Phase 1/2 POTENTIATE clinical trial of patients with cancer harboring oncogene amplifications Number: 3631 Session Category: Clinical Research Session Title: Biomarkers in Clinical Trials Session Date and Time: Monday Apr 8, 2024, 1:30 PM - 5:00 PM PT Location: Poster Section 40 Poster Board Number: 9 Historically, clinical CHK1 inhibitor programs have lacked effective clinical PD biomarker assays. The findings showed that phosphorylated-CHK1 Ser345 (pCHK1-S345) is a useful pharmacodynamic (PD) biomarker for confirming clinical on-target activity of BBI-355 and could potentially inform the pharmacologically active range of BBI-355 in clinical development. In addition to preclinical data, increased pCHK1-S345 expression by immunohistochemistry in skin biopsies from patients treated with BBI-355 in the ongoing POTENTIATE clinical study were also observed, marking the first, real-time analysis of PD activity from a CHK1 inhibitor in humans. Title: Extrachromosomal DNA (ecDNA) amplification of multi-drug resistance genes results in acquired resistance to taxane-based chemotherapy Abstract Number: 5870 Session Category: Experimental and Molecular Therapeutics Session Title: Mechanisms of Drug Resistance 3 Session Date and Time: Tuesday Apr 9, 2024, 1:30 PM - 5:00 PM PT Location: Poster Section 24 Poster Board Number: 14 Early insights into the role of ecDNA in driving resistance to paclitaxel, a taxane chemotherapy, are revealed and highlight the importance of ecDNA-directed therapies as a potential treatment option for many patients that have chemotherapy-resistant disease. Chemotherapy remains standard of care for many cancer patients, however, resistance to chemotherapy often develops and has been associated with the emergence of multi-drug resistance (MDR) gene amplification, such as ABCB1. These preclinical findings showed that ecDNA-enabled MDR gene amplification can cause short-and long-term resistance to paclitaxel, potentially driving resistance to chemotherapy in patients and underscoring the broad need for ecDTx for chemotherapy-resistant patient populations. About BBI-355 Boundless Bio’s lead ecDNA-directed therapy (ecDTx), BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) being studied in the ongoing, first-in-human, Phase 1/2 POTENTIATE clinical trial (NCT05827614) in patients with oncogene amplified cancers. CHK1 is a master regulator of cells’ response to replication stress (RS). RS is elevated in ecDNA-enabled oncogene amplified cancer cells and, because of this, represents a key vulnerability of those cells. BBI-355 was designed to exploit the elevated RS in ecDNA-enabled oncogene amplified cancer cells by disrupting proper CHK1 function in regulating RS and thereby facilitating catastrophic RS to preferentially kill cancer cells relative to healthy cells. About Boundless Bio Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification and observed in more than 14% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapy (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) and is being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Boundless Bio’s second ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) and recently entered a Phase 1/2 clinical trial in cancer patients with resistance gene amplifications. Leveraging its Spyglass platform, Boundless Bio has additional programs advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA. For more information, visit . Follow us on LinkedIn and Twitter. Forward-Looking Statements Boundless Bio cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the potential therapeutic benefits of our ecDTx in treating patients with oncogene amplified cancers; and the possibility to extend potential applicability of ecDTx beyond targeted therapy resistance. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: we are early in our development efforts and our approach to discover and develop ecDTx directed against ecDNA in oncogene amplified cancers is novel and unproven; results from preclinical studies or early clinical trials not necessarily being predictive of future results; potential delays in the commencement, enrollment, data readouts or completion of clinical trials or preclinical studies; our dependence on third parties in connection with clinical trials, preclinical studies, ecDNA diagnostic development, and manufacturing; unfavorable results from clinical trials or preclinical studies; unexpected adverse side effects or inadequate efficacy of our ecDTx that may limit their development, regulatory approval, and/or commercialization; regulatory developments in the United States and foreign countries; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the final prospectus dated March 27, 2024 that we filed with the SEC and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Clinical StudyAACR

04 Apr 2024

·firstwordpharma.com

Novartis aims for broader Pluvicto use after prostate cancer study update

Novartis confirmed plans Thursday to file for a label expansion of its radioligand drug Pluvicto (lutetium 177 vipivotide tetraxetan) in the second half of 2024, aiming to secure approval for its use in advanced prostate cancer patients prior to treatment with taxane-based chemotherapy.The regulatory submission will be based on updated results from the Phase III PSMAfore study, which evaluated Pluvicto in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with androgen receptor pathway inhibitors (ARPI).OS prompted previous delayIn findings from the second interim analysis of PSMAfore with 45% of events, unveiled last October at the European Society for Medical Oncology (ESMO) congress, Pluvicto demonstrated a 59% benefit on the primary endpoint of radiographic progression-free survival (rPFS) compared to daily oral androgen therapy.However, the study's design allowed control patients to receive Pluvicto at disease progression – something that muddied up the interpretation of overall survival (OS) data given the exceptionally high 84% rate of treatment crossover. At the time, Novartis said Pluvicto was associated with a 16% higher risk of death before adjusting for crossover; but when crossover events were taken into account, the drug exhibited a 20% decrease in mortality risk.Nevertheless, questions about the OS data prompted Novartis to postpone its projected timeline for seeking a broader US label from the third quarter of 2023 to sometime this year. For more, see – KOL Views Q&A: PSMAfore not a win for Pluvicto but Novartis still has path to growth in CRPC.HR of less than 1.0On Thursday, Novartis said that "at approximately 75% of the targeted information fraction for the trial's primary endpoint of rPFS, Pluvicto demonstrated a hazard ratio (HR) of less than 1.0 compared to an alternative ARPI in the intent-to-treat population, unadjusted for crossover to Pluvicto treatment."Novartis stated that rPFS and other secondary efficacy endpoints were "consistent" with interim results presented in 2023, while an additional eight months of follow-up data revealed no new safety concerns. Full results will be shared at an upcoming medical meeting.Pluvicto is already approved in the US for patients with PSMA-positive mCRPC who have been treated with ARPI and taxane-based chemotherapy. The radiopharmaceutical became Novartis' fastest-growing drug in 2023 with sales more than tripling to $980 million.

Clinical ResultPhase 3Drug Approval

08 Mar 2024

·www.businesswire.com

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

IRVINE, Calif. & AMSTERDAM--( BUSINESS WIRE )-- Agendia ® , Inc. , announced today it will share new data from the ongoing prospective, observational FLEX Trial ( NCT03053193 ) in two poster presentations at the 41 st Annual Miami Breast Cancer Conference (MBCC), taking place March 7 – 10 th , 2024. The first poster, titled MammaPrint ® and BluePrint ® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.), investigates the associations between MammaPrint and BluePrint classifications, therapy regimen, and the likelihood of achieving a pathologic Complete Response (pCR). Researchers looked at patients who had hormone receptor-positive (HR+), Human Epidermal Growth Factor Receptor (HER) 2-negative early-stage breast cancer – categorized as MammaPrint High Risk – who had been treated with either a combination of two (taxane and cyclophosphamide, TC) or three (TC with anthracycline, AC-T) types of neoadjuvant chemotherapy. Patients were then further stratified into MP High 1 and High 2 categories, and further stratified by BluePrint subtype of Luminal and Basal. Results showed that patients with MP High 2 tumors, including Luminal B and Basal subtypes, are more likely to achieve a pCR in response to AC-T, while the addition of anthracycline to the therapy regimen does not appear to improve pCR rates for patients with MP High 1, Luminal B-type tumors. The second poster, titled Prediction of chemotherapy benefit by MammaPrint ® in patients with HR+HER2-early-stage breast cancer from real-world evidence studies (Audeh, W., et al.), used data from patients with HR+ HER2-negative early-stage breast cancer enrolled in the FLEX and NBRST trials to generate a prediction of the magnitude of chemotherapy benefit based upon a patient’s genomic risk, looking at the MammaPrint index more closely as a continuous variable. Researchers examined the association of the MammaPrint index with benefit from chemotherapy by evaluating two clinical endpoints, the likelihood of pCR in response to neoadjuvant chemotherapy, and the five-year outcome among patients who received chemotherapy and endocrine therapy or endocrine therapy alone. Consistent with results found in the landmark MINDACT trial, this study showed that the MammaPrint index demonstrates strong efficacy in predicting low chemosensitivity in Low Risk and Ultra Low Risk tumors, reinforcing that these groups do not derive significant chemotherapy benefit. However, it was also observed that chemotherapy effectiveness increased as MammaPrint risk increased in High 1 and High 2 tumors, as evidenced by both pCR rates and 5-year outcomes, demonstrating that the overall benefit of chemotherapy increases as MammaPrint risk increases. Taken together, these findings indicate the utility of MammaPrint to predict neoadjuvant and adjuvant chemotherapy benefit in this patient population. “In this unique real world evidence FLEX study, we were able to look at chemosensitivity for patients who had received neoadjuvant treatment and the chemo benefit for patients who are treated with systemic therapy after surgery, showing that MammaPrint is predictive of chemotherapy benefit in both cases. The FLEX Trial, with over 16,000 women enrolled, is now allowing us to look at clinical outcomes as well as analyzing whole transcriptome data,” said William Audeh, MD, MS, Chief Medical Officer of Agendia. “The data we’re sharing at the Miami Breast Cancer Conference confirms that gene expression profiling with these assays identify who may benefit from chemotherapy, and may prove helpful in regimen selection as well. We look forward to further exploring the capabilities of MammaPrint and BluePrint for women across the entire spectrum of breast cancer risk and subtype.” The goal of Agendia’s research is to increase the likelihood of managing each individual’s cancer diagnosis by delivering a customized treatment plan to the patients most likely to benefit based on the unique features of their tumor. About Agendia Agendia is a leading provider of innovative solutions in the field of precision oncology. With a focus on early-stage breast cancer, Agendia offers reliable biological insights that inform personalized treatment decisions for patients and their care teams. Their advanced genomic assays, MammaPrint ® + BluePrint ® , enable clinicians to quickly identify the most effective treatment plan, minimizing the risk of both under- and over-treatment. Founded in 2003 in Amsterdam, Agendia is headquartered in Irvine, California with a state-of-the-art laboratory facility. Led by world-renowned scientists and oncologists, Agendia is committed to advancing genomic insights through ongoing research. This includes the notable FLEX Study– the world's largest whole transcriptome Real-World Evidence-based Breast Cancer database which aims to revolutionize precision in breast cancer management. With cutting-edge technology, research and innovation, Agendia strives to shape the future of precision oncology and make a significant impact in the fight against breast cancer. About MammaPrint MammaPrint ® is a gene expression profiling test that reveals the distinct underlying biology of an early-stage tumor to determine its risk of spreading. As the only FDA-cleared gene expression profiling test to assess a woman's risk of distant metastasis, MammaPrint ® provides critical answers that help inform the future of her treatment plan at the point of diagnosis, including the timing and benefit to chemotherapy and endocrine therapy. MammaPrint® listens to the signals from 70 key genes in a woman’s tumor to stratify her risk within four distinct categories - ranging from UltraLow, Low, High 1, and High 2– to fuel a right-sized care plan tailored to her biology and her life's plans. About BluePrint BluePrint ® is a gene expression profiling test that reveals the driving forces behind a tumor’s growth at the earliest stage possible in a woman’s breast cancer care journey to help optimize and personalize treatment planning. As the only molecular subtyping test available in the U.S., BluePrint® goes where pathology cannot, offers critical insights that providers may otherwise have not known to act on, and gives women the best chance to return to a life not defined by cancer. BluePrint® measures the activity of 80 key genes that are involved in a tumor's growth to classify a tumor as Luminal-type, HER2-type, or Basal-type, each of which warrant distinct treatment pathways. By revealing the distinct underlying biology of a woman's tumor, BluePrint® can catch often misclassified, yet highly aggressive, Basal tumors, so women can be prescribed the most appropriate treatment from the start.

Clinical ResultClinical Study

100 Deals associated with Proliposomal intravesical paclitaxel

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB01229

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 2	-	TesoRx Pharma LLC	-
Malignant Pleural Effusion	Preclinical	US	LIPAC Oncology LLCStartup	11 Jun 2024
Ovarian Cancer	Preclinical	US	LIPAC Oncology LLCStartup	11 Jun 2024
Peritoneal Neoplasms	Preclinical	US	LIPAC Oncology LLCStartup	11 Jun 2024
Non-Muscle Invasive Bladder Neoplasms	Discovery	US	TesoRx Pharma LLC	17 May 2018
Urothelial Carcinoma of the Urinary Bladder	Discovery	US	TesoRx Pharma LLC	17 May 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GI2023 Manual	Not Applicable	Stomach Cancer Third line CLDN18 Expression	121	fluoropyrimidine+platinum+taxanes (CLDN18.2 high)	(lmhnudrfdp) = ysxcqvciyr ktpoprxrqe (zfykqemzbi, 10.7 - 32.4)	Positive	24 Jan 2023
				fluoropyrimidine+platinum+taxanes (CLDN18.2 low)	(lmhnudrfdp) = badfmbrjfd ktpoprxrqe (zfykqemzbi, 14.8 - 21.4)
ESMO_IO2022	Not Applicable	Non-Small Cell Lung Cancer First line	102	Sintilimab + platinum + taxanes	(cawjfwtjse) = bxsjonncpq ltpuaglnva (xkwhzefmxs ) View more	-	08 Dec 2022
				Sintilimab + platinum + pemetrexed	(cawjfwtjse) = shhrjnvluw ltpuaglnva (xkwhzefmxs ) View more
ASCO2022	Not Applicable	Squamous Cell Carcinoma of Head and Neck	99	Taxanes + Cetuximab	(ihpolukoye) = qsjvezwqvz gdifwgenph (xdnfzvbpta ) View more	-	02 Jun 2022
				Taxanes + Cetuximab + Platinum	(andbyiojgd) = jhzjzuhhev ugpbtnubhm (qcqmjcviqu )
NCT03081858 (Biospace) Manual	Phase 1/2	Recurrent Bladder Cancer	6	LiPax	(nsmmxhtzoc) = bbtzjphwmx jzuxlluusz (dmqbdcnngf ) View more	Positive	18 May 2020
ASCO_GU2020	Not Applicable	Metastatic castration-resistant prostate cancer	-	taxanes (High glutamine levels)	(bmovgtbopj) = xwdzucitkb wyvdoncovk (fjoohjtbsu ) View more	Positive	19 Feb 2020
				taxanes (Low glutamine levels)	(bmovgtbopj) = pyspmgikka wyvdoncovk (fjoohjtbsu ) View more
ESMO2018	Not Applicable	Breast Cancer Adjuvant	-	Taxane + Cyclophosphamide combination (TC)	(rmkzgkcdih) = jzurjtcgoe oozszerixc (uyxyzpurcm )	-	22 Oct 2018
				Cyclophosphamide + Anthracycline combination (TaxAC)	(rmkzgkcdih) = lvcbopwloz oozszerixc (uyxyzpurcm )
AACR2017	Not Applicable	Locally advanced breast cancer	63	Chemotherapy based on anthracyclines and taxanes	wisftnmzkn(bqssfxwnoy) = ifwxohuhhi oxrbtfyttq (ygmwaovqfw )	-	01 Jul 2017
GIM13-AMBRA (ASCO2017)	Not Applicable	Metastatic breast cancer Adjuvant	791	Taxanes	tnoarvhlhc(wxcwdmvtgx) = cemksnimeu rwvfgwkdun (nfyeapzmvi )	-	30 May 2017
AACR2016	Not Applicable	Metastatic castration-resistant prostate cancer	-	taxane (Metastatic castration resistant prostate cancer samples)	cvwhcjownt(rooptgqmqj) = iapjwxdoth uyjtahqvzv (xrtwwpxobe ) View more	-	15 Jul 2016
TAX-325 (AACR2016)	Not Applicable	Stomach Cancer	-	taxanes (Diffuse histology)	(yofeomwvqv) = tcpwatlofe umwimzswyl (cstpkxfpzw )	-	15 Jul 2016
				taxanes (Non-diffuse histology)	(yofeomwvqv) = ynxpvfgbzw umwimzswyl (cstpkxfpzw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis